Noticias de ABUS_US

Noticias del mercado

Últimas noticias sobre ABUS_US — 42 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ABUS_US ✕ 42 resultados
14/04/2026 ABUS_US — ADVFN
Form 8-K - Current report
14/04/2026 ABUS_US — Stock Titan
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote
09/04/2026 ABUS_US — MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - What's Next?
24/03/2026 ABUS_US — Minichart
Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information
23/03/2026 ABUS_US — Stock Titan
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement
23/03/2026 ABUS_US — Yahoo Finance
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23/03/2026 ABUS_US — GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
05/03/2026 ABUS_US — Delaware Business Now
Moderna reaches agreement in COVID-19 intellectural property dispute
04/03/2026 ABUS_US — The Manila Times
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
04/03/2026 ABUS_US — Benzinga
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
03/03/2026 ABUS_US — GlobeNewswire
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
03/03/2026 ABUS_US — Stock Titan
$2.25 billion Moderna deal ends COVID vaccine patent fight
03/03/2026 ABUS_US — Stock Titan
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement
03/03/2026 ABUS_US — TipRanks
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna
03/03/2026 ABUS_US — Law360
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight
03/03/2026 ABUS_US — Stock Titan
Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal
27/02/2026 ABUS_US — DirectorsTalk Interviews
Arbutus Biopharma Corporation (ABUS) Stock Analysis: Navigating a 22% Upside Potential Amidst Biotech Challenges
06/02/2026 ABUS_US — Stock Titan
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight
05/02/2026 ABUS_US — JD Supra
Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nanoparticle Case
03/02/2026 ABUS_US — Seeking Alpha
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts (NASDAQ:ABUS)

Página 2 de 3

keyboard_arrow_up